BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 21668340)

  • 1. Basal plus basal-bolus approach in type 2 diabetes.
    Ampudia-Blasco FJ; Rossetti P; Ascaso JF
    Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S75-83. PubMed ID: 21668340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Refining basal insulin therapy: what have we learned in the age of analogues?
    Devries JH; Nattrass M; Pieber TR
    Diabetes Metab Res Rev; 2007 Sep; 23(6):441-54. PubMed ID: 17668418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective switch from premixed to basal-prandial insulin to achieve glycemic goals in type 2 diabetes.
    Lavernia F
    Postgrad Med; 2010 May; 122(3):28-32. PubMed ID: 20463411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
    Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J
    J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C; Hernández Herrero C; Rivas Fernández M
    Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
    Hermansen K; Dornhorst A; Sreenan S
    Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy.
    Yokoyama H; Tada J; Kamikawa F; Kanno S; Yokota Y; Kuramitsu M
    Diabetes Res Clin Pract; 2006 Jul; 73(1):35-40. PubMed ID: 16513202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus.
    Yki-Järvinen H
    Diabetes Metab Res Rev; 2002; 18 Suppl 3():S77-81. PubMed ID: 12324990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why, when and how to initiate insulin therapy in patients with type 2 diabetes.
    Tibaldi J; Rakel RE
    Int J Clin Pract; 2007 Apr; 61(4):633-44. PubMed ID: 17394436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes.
    Ligthelm RJ; Mouritzen U; Lynggaard H; Landin-Olsson M; Fox C; le Devehat C; Romero E; Liebl A
    Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):511-9. PubMed ID: 17115349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redefining insulin therapy in type 2 diabetes mellitus.
    Rosenstock J
    Postgrad Med; 2004 Nov; 116(5 Suppl Exploring):21-9. PubMed ID: 19667676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
    Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
    Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens: a randomized trial.
    Strojek K; Shi C; Carey MA; Jacober SJ
    Diabetes Obes Metab; 2010 Oct; 12(10):916-22. PubMed ID: 20920045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin analogs versus human insulin in type 2 diabetes.
    Migdalis IN
    Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S102-4. PubMed ID: 21864739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosing of insulin glargine in the treatment of type 2 diabetes.
    Barnett A
    Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study.
    De Mattia G; Laurenti O; Moretti A
    Acta Diabetol; 2009 Mar; 46(1):67-73. PubMed ID: 19030772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addressing hyperglycemia from hospital admission to discharge.
    Moghissi ES
    Curr Med Res Opin; 2010 Mar; 26(3):589-98. PubMed ID: 20078323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Premixed insulin treatment for type 2 diabetes: analogue or human?
    Garber AJ; Ligthelm R; Christiansen JS; Liebl A
    Diabetes Obes Metab; 2007 Sep; 9(5):630-9. PubMed ID: 17697056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical strategies for controlling peaks and valleys: type 1 diabetes.
    Bolli GB
    Int J Clin Pract Suppl; 2002 Jul; (129):65-74. PubMed ID: 12166610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs.
    Lankisch MR; Ferlinz KC; Leahy JL; Scherbaum WA;
    Diabetes Obes Metab; 2008 Dec; 10(12):1178-85. PubMed ID: 19040645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.